| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 11/12/2009 | US20090280066 Methods and compounds for the treatment of mucus hypersecretion |
| 11/12/2009 | US20090280058 Delivery Of Double-Stranded RNA Into The Central Nervous System |
| 11/12/2009 | DE102008023820A1 Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen Agents for the treatment and / or prophylaxis of an autoimmune disease and the formation of regulatory T-cells |
| 11/12/2009 | DE102008022520A1 Feste Arzneimittelformulierung mit verzögerter Freisetzung Solid pharmaceutical formulation with sustained release |
| 11/12/2009 | CA2725227A1 Antiviral cell penetrating peptides |
| 11/12/2009 | CA2723887A1 Peptide homing to brain tumors |
| 11/12/2009 | CA2723761A1 Agent for the treatment and/or prophylaxis of an autoimmune disease and for the formation of regulatory t cells |
| 11/12/2009 | CA2723760A1 Biomimetic cell scaffolds |
| 11/12/2009 | CA2723744A1 Sialic acid to support salivation |
| 11/12/2009 | CA2723564A1 Sialic acid to support the immune system in the elderly |
| 11/12/2009 | CA2723563A1 Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor |
| 11/12/2009 | CA2723558A1 Compositions of gnrh related compounds and processes of preparation |
| 11/12/2009 | CA2723553A1 Solid pharmaceutical formulation with delayed release |
| 11/12/2009 | CA2723541A1 Compositions of peptides and processes of preparation thereof |
| 11/12/2009 | CA2723434A1 Methods and compositions for oral administration of exenatide |
| 11/12/2009 | CA2723144A1 Ophthalmic device, and method of use thereof, for increasing ocular boundary lubrication |
| 11/12/2009 | CA2722944A1 Therapeutic modulation of ocular surface lubrication |
| 11/12/2009 | CA2722913A1 Therapeutic replenishment and enrichment of ocular surface lubrication |
| 11/12/2009 | CA2722821A1 Colostrum-derived fraction for wound healing and skin care |
| 11/12/2009 | CA2722803A1 Human bone-forming cells in the treatment of conditions and bone diseases associated with immunodeficiency or immunosuppression |
| 11/12/2009 | CA2722127A1 Compositions and methods for inhibiting shiga toxin and shiga-like toxin |
| 11/12/2009 | CA2721683A1 Modified factor ix polypeptides and uses thereof |
| 11/12/2009 | CA2720685A1 Affinity matured crig variants |
| 11/12/2009 | CA2719706A1 Compositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof |
| 11/11/2009 | EP2116616A2 Genes differentially expressed in activated T cells and uses thereof |
| 11/11/2009 | EP2116604A1 Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
| 11/11/2009 | EP2116603A2 Antimicrobial peptides |
| 11/11/2009 | EP2116561A1 Multibranched polyoxyalkylene derivative |
| 11/11/2009 | EP2116552A2 Peptides, derivatives thereof, process for producing the same, strain producing the same, and antiviral agent comprising the same as active ingredient |
| 11/11/2009 | EP2116551A1 Compositions and methods for the treatment of immune related diseases |
| 11/11/2009 | EP2116265A2 Reduced-viscosity concentrated protein formulations |
| 11/11/2009 | EP2116264A1 Preparation for transnasal application |
| 11/11/2009 | EP2116262A2 Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy |
| 11/11/2009 | EP2116259A1 TACI-immunoglobulin fusion proteins |
| 11/11/2009 | EP2116255A1 Therapeutic agent for spinal cord injury |
| 11/11/2009 | EP2116254A1 Tumor vaccine, a method for producing a tumor vaccine and a method for carrying out antitumor immunotherapy |
| 11/11/2009 | EP2116240A1 Augmented cognitive training with HT0712 |
| 11/11/2009 | EP2116230A2 Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
| 11/11/2009 | EP2116228A1 Novel cyclosporin analog microemulsion preconcentrates |
| 11/11/2009 | EP2115465A2 Surgical applications for bmp binding protein |
| 11/11/2009 | EP2115156A2 Multimeric elp fusion constructs |
| 11/11/2009 | EP2115146A2 Lactococcus promoters and uses thereof |
| 11/11/2009 | EP2115134A1 Methods |
| 11/11/2009 | EP2114998A1 Novel multimeric molecules, method for preparing same and use thereof in the preparation of drugs |
| 11/11/2009 | EP2114992A2 Anti-bacterial peptides and methods of treating diseases using same |
| 11/11/2009 | EP2114989A2 Natural polypeptides for oral health care |
| 11/11/2009 | EP2114988A2 Peptides and their use |
| 11/11/2009 | EP2114986A1 Template-fixed peptidomimetics |
| 11/11/2009 | EP2114985A2 Multivariable antigens complexed with targeting humanized monoclonal antibody |
| 11/11/2009 | EP2114924A2 Co-crystals and pharmaceutical compositions comprising the same |
| 11/11/2009 | EP2114460A2 Methods and compositions for the disruption of biofilms |
| 11/11/2009 | EP2114459A1 Recombinant viral vectors for prevention and protection against alphavirus infection |
| 11/11/2009 | EP2114456A2 Stabilization of aqueous compositions of proteins with displacement buffers |
| 11/11/2009 | EP2114442A1 Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| 11/11/2009 | EP2114441A1 The use of alkaline phosphatase in the treatment of reduced renal function |
| 11/11/2009 | EP2114439A1 Use of somatostatin analogs in cluster headache |
| 11/11/2009 | EP2114438A1 An insulinotropic complex using an immunoglobulin fragment |
| 11/11/2009 | EP2114436A1 Trkb agonists for treating autoimmune disorders |
| 11/11/2009 | EP2114435A1 Modulators of sclerostin binding partners for treating bone-related disorders |
| 11/11/2009 | EP2114434A1 Method for inducing thrombopoiesis |
| 11/11/2009 | EP2114433A2 Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation |
| 11/11/2009 | EP2114430A1 Trpv1+ sensory neurons control of beta-cell stress and islet inflammation in diabetes |
| 11/11/2009 | EP2114429A2 Compositions and methods to prevent cancer with cupredoxins |
| 11/11/2009 | EP2114428A2 Triazole macrocycle systems |
| 11/11/2009 | EP2114427A1 Peptides for treatment of conditions associated with nitric oxide |
| 11/11/2009 | EP2114426A2 Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat |
| 11/11/2009 | EP2114422A1 Osteopontin for the prediction and treatment of cardiovascular diseases |
| 11/11/2009 | EP2114371A1 Transport of drugs via the blood-brain barrier by means of apolipoproteins |
| 11/11/2009 | EP2114239A1 Model predictive method and system for controlling and supervising insulin infusion |
| 11/11/2009 | EP2114145A2 Phenylalkylcarboxylic acid delivery agents |
| 11/11/2009 | EP2114130A2 Animal model for adhd |
| 11/11/2009 | EP1694291B1 Endoparasiticidal agents for topical application |
| 11/11/2009 | EP1603541B1 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF |
| 11/11/2009 | EP1498421B1 Gamma-secretase inhibitors |
| 11/11/2009 | EP1450856B1 Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use |
| 11/11/2009 | EP1372634B1 Use of fumaric acid amides |
| 11/11/2009 | EP1317278B1 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| 11/11/2009 | EP1315826B1 Enhanced in vitro synthesis of active proteins containing disulfide bonds |
| 11/11/2009 | EP1315812B1 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 11/11/2009 | EP1278874B1 Hybrid protein and vector encoding the same for inhibition of angiogenesis |
| 11/11/2009 | EP1255726B1 (r)-2-aryl-propionamides, useful in the inhibition of il-8 induced chemiotaxis of neutrophils |
| 11/11/2009 | EP1242118B1 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 11/11/2009 | EP1191943B1 Anti-allergic peptides |
| 11/11/2009 | EP1181314B1 Polyepitopic proteinic fragments of the hiv nef protein, production and use thereof in vaccinations |
| 11/11/2009 | EP1181048B1 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor |
| 11/11/2009 | CN101578373A Fusion peptide therapeutic compositions |
| 11/11/2009 | CN101578368A Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity |
| 11/11/2009 | CN101578365A Vascular endothelial cell-binding peptide |
| 11/11/2009 | CN101578294A Inhibitors of hepatitis C virus |
| 11/11/2009 | CN101578107A Novel compounds and their effects on feeding behaviour |
| 11/11/2009 | CN101578106A HGF preparation |
| 11/11/2009 | CN101578105A Use of MAGE A3-protein D fusion antigen in immunotherapy combined with surgery, chemotherapy or radiotherapy for the treatment of cancer |
| 11/11/2009 | CN101578104A Antimicrobial decapeptide oral hygiene treatment |
| 11/11/2009 | CN101578103A Agent for injection purposes comprising antibiotic, and solution for injection comprising the agent |
| 11/11/2009 | CN101575606A Clone, expression and application of tender Eimeria tenella protein kinase (EtPK) gene |
| 11/11/2009 | CN101575379A Soluble VEGFR difunctional fusion receptors, preparation method and use thereof |
| 11/11/2009 | CN101575377A Human cytokine as ligand of zalpha receptor and use thereof |
| 11/11/2009 | CN101575372A Analogue of human keratinocyte growth factor-1 and preparation method and application thereof |
| 11/11/2009 | CN101575367A Chinese yam glycosidoprotein and preparation method thereof |
| 11/11/2009 | CN101575365A Antiviral protein and preparation method and application thereof |